1 Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, J Grarup, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich , R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren, A Mocroft on behalf of EuroSIDA.
HIV Med. 2018;19(2):102-117. abstract
2 Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro, J. A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, for the TB:HIV study in EuroCoord.
J Infect. 2018;76(1):44-54. Abstract
3 The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A for EuroSIDA in EuroCOORD.
HIV Med. 2018;19(2):90-101. Abstract
4 Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? A Mocroft, K Laut, P Reiss, J Gatell, V Ormaasen, M Cavassini, V Hadziosmanovic, K Mansinho, C Pradier, M Vasylyev, V Mitsura, L Vandekerckhove, L Ostergaard, A Clarke, O Degen, F Mulcahy, A Castagna, Z Sthoeger, L Flamholc, D Sedláček, I Mozer-Lisewska, JD Lundgren for the EuroSIDA study.
AIDS. 2018;32(2):205-215. Abstract
5 Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort. A Roen, K Laut, A Pelchen-Matthews, E Borodulina, L Caldeira, A Clarke, B Clotet, A d'Arminio Monforte, G Fätkenheuer, JM. Gatell Artigas, IKarpov, A Kuznetsova, G Kyselyova, I Mozer-Lisewska, F Mulcahy, L Ragone, A Scherrer, V Uzdaviniene, L Vandekerckhove, V Vannappagari, L Ostergaard, A Mocroft for the EuroSIDA study
HIV Med. 2018;19(4):252-260. Abstract
6 Long-term Effectiveness of Recommended Boosted PI-Based Antiretroviral Therapy in Europe. Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Parades R, Lundgren JD for the EuroSIDA study.
HIV Med. 2018;19(5):324-338. Abstract
7 Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law, M, Lundgren JD, Sabin C, On behalf of the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.
J Int AIDS Soc. 2018;21(3). Abstract
8 Abacavir use and risk of recurrent myocardial infarction.Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.
AIDS. 2018;32(1):79-88. Abstract
9 Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Laut KG, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, Kovari H, Blaxhult A, Zangerle R, Trofimora T, Knysz B, Zilmer K, Kouzovatova E, Staub T, Raben D, Lundgren JD, Mocroft A, Kirk O for the EuroSIDA study.
Eurosurveillance 2018 Volume 23, Issue 21. Article
10 The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, M Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri.
Persistent dispAntivir Ther. 2018;23(2):105-116. Abstract
11 Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. L Ryom, JD Lundgren, W El-Sadr, P Reiss, O Kirk, M Law, A Phillips, R Weber, E Fontas, A d’ Arminio Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft. On behalf of the D:A:D Study group
Lancet HIV. 2018 Jun;5(6):e291-e300. Abstract
12 Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma.
L Shepherd, L Ryom, M Law, C Ingrid Hatleberg, S de Wit, A d'Arminio Monforte, M Battegay, A Phillips, F Bonnet, P Reiss, C Pradier, A Grulich, C Sabin, J Lundgren, A Mocroft,
J Natl Cancer Inst. 2018;110(6):598-607. Abstract
13 Associations between serum albumin and serious non-AIDS events among people living with HIV. A Ronit, CI Hatleberg, L Ryom, F Bonnet, W El-Sadr, P Reiss, R Weber, C Pradier, S De Witt, M Law, A d’Arminio Monforte, J Lundgren, A Mocroft, AN Phillips, C Sabin, for the D:A:D Study group
AIDS. 2018;32(13):1837-1848. Abstract
14 Body Mass Index and the Risk of serious non-AIDS events and all cause mortality in treated HIV-positive individuals: D:A:D Cohort Analysis
AC Achhra, C Sabin, L Ryom, C Hatleberg, A d’Aminio Monforte, S de Wit, A Phillips, C Pradier, R Weber, P Reiss, W El-Sadr, F Bonnet, A Mocroft, J Lundgren, MG Law for the D:A:D study group
J Acquir Immune Defic Syndr. 2018;78(5):579-588. Abstract
15 Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. L Peters, K Laut, C Resnati, S Del Campo, C Leen, K Falconer, T Trofimova, D Paduta, J Gatell, A Rauch, K Lacombe, P Domingo, N Chkhartishvili, R Zangerle, R Matulionyte, V Mitsura, T Benfield, K Zilmer. I Khromova, J Lundgren, J Rockstroh, A Mocroft for the EuroSIDA study.
AIDS. 2018;32(14):1995-2004. Abstract
16 Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the D:A:D Study. CI Hatleberg, L Ryom, A d’Arminio Monforte, E Fontas, P Reiss, O Kirk, W El-Sadr, A Phillips, S de Wit, F Dabis, R Weber, M Law, JD Lundgren, C Sabin On behalf of the Data collection of Adverse events of anti-HIV Drugs (D:A:D) Study Group
HIV Med. 2018;19(9):605-618. Epub 2018 Jul 18. Abstract
17 Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. A Pelchen-Matthews, L Ryom, A Borges, S Edwards, C Duvivier, C Stefan, H Sambatakou, K Maciejewska, J Joaquín Portu, J Weber, O Degen, A Calmy, DH Reikvam, D Jevtovic, L Wiese, J Smidt, T Smiatacz, G Hassoun, A Kuznetsova, B Clotet, J Lundgren, A Mocroft for the EuroSIDA study.
AIDS. 2018;32(16):2405-2416. Abstract
18 Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. Peters L, Mocroft A. Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J for the EuroSIDA study.
Antivir Ther. 2018;23(5):405-413. Abstract
19 Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. K Laut, L Shepherd, M Gottfredsson, D Sedlacek, B Knysz, J Begovac, R Radoi, B Schmied, N Chkhartishvili, E Florence, M Ristola, G Fätkenheuer, F Mulcahy, P Schmid, E Kuzovatova, D Paduta, J Smidt, P Domingo, J Szlávik, J Lundgren, A Mocroft, O Kirk on behalf of the EuroSIDA study group
AIDS. 2018;32(18):2807-2819. Abstract
20 Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. Caro-Vega, A. Schultze, A.M. W. Efsen, F.A. Post, A. Panteleev, A. Skrahin, J.M. Miro, E. Girardi, D.N. Podlekareva, J.D. Lundgren, j. Sierra-Madero, J. Toibaro, J. Andrade-Villanueva, S. Tetradov, J. Fehr, J. Caylà, M.H. Losso, R.F. Miller, A. Mocroft, O. Kirk, B. Crabtree-Ramírez.
BMC Infect Dis. 2018;18(1):191. Abstract
Total Publications December 2018: 284